CYP19A1 and colorectal carcinoma: Our findings provide a new perspective on the role of mitochondria in CRC chemoresistance, suggesting that targeting the CYP19A1/estrogen/complex I axis could be a promising strategy to overcome drug resistance and enhance treatment efficacy.